New research suggests that patients who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Published data in a prominent medical journal points out that while obese individuals can lose a large proportion of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month after stopping.
"Individuals buying these drugs should be aware of the danger of rapid rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
This pace of regain means a return to starting weight within about one and a half years.
Comparing Treatments
The research, which looked at 37 of trials involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through lifestyle changes alone generally have a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Doctors believe the mechanism of the jabs is key to understanding the heightened regain.
These medications imitate a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 levels far above than normal might result in the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means appetite is unsuppressed, making overeating a significant risk."
A Lifelong Disease?
Health authorities advise the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, due to the high risk of weight regain, the therapy should be considered life-long.
This opinion is supported by drug manufacturers, who state that the results "underscore the chronic nature of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Individuals who have stopped the jabs report a powerful resurgence of appetite.
"It was like a trigger activating and you're instantly starving," recalled an individual.
This difficulty is worsened if patients have not established sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates suggest that millions of adults in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is greater among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and maintained weight loss likely depends on ongoing lifestyle changes.
